24 results on '"Byers, L.A."'
Search Results
2. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix
3. P2.10-01 Transcriptional Diversity of Emerging Cell Populations in Refractory Small Cell Lung Cancer Biopsies and Xenografts
4. MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach
5. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
6. 1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
7. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
8. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
9. SCLC subtype-enriched biomarkers define positioning of Aurora B inhibitor combination with venetoclax
10. 1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer
11. 1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models
12. 1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models
13. Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
14. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
15. Genomic landscape of small cell neuroendocrine cervical cancer
16. OA 13.01 CD38-Mediated Immunometabolic Suppression as a Mechanism of Resistance to PD-1/PD-L1 Axis Blockade
17. MA 01.10 Outcome Based on Baseline Total Lymphocyte Count & Neutrophil-To-Lymphocyte Ratio in Extensive Stage Small-Cell Lung Cancer
18. 1749P - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
19. 243 Modulation of PI3K/mTOR pathway following PARP inhibition in small cell lung cancer
20. 242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models
21. 435 A pan-cancer tumor-derived epithelial-to–mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMT
22. 388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors
23. Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy
24. 171 Poster - SCLC subtype-enriched biomarkers define positioning of Aurora B inhibitor combination with venetoclax.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.